Exchange: NYSE·Updated 06:52 PM EDT
ELV logo

ELVElevance Health Inc

$370.18
$0.42
(0.11%)
Today
Closed $376.40
$6.22
(1.65%)
After Hours
Reported EarningsJul 15
Mkt Cap$81.54B
Vol783,889.00
News
all
press releases
Teladoc Health Q2 Earnings Beat Estimates on Integrated Care Strength
TDOC tops adjusted earnings estimates despite a revenue miss, as Integrated Care and international growth help cushion BetterHelp weakness and a lower 2026 outlook.
Zacks
More News
ENSG Q2 Earnings Beat Estimates on Growing Occupancy, '26 View Raised
Ensign Group beats Q2 earnings and raises its 2026 outlook as higher occupancy, patient days and acquired facilities drive revenue growth.
Zacks
Humana Q2 Earnings Beat Estimates on Medical Membership Growth
HUM's Q2 earnings top estimates as medical membership growth, premium gains and CenterWell strength lift results despite higher costs.
Zacks
Centene Q2 Earnings Beat Estimates on Increasing Premiums
CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.
Zacks
UHS Beats Q2 Earnings and Revenue Estimates Despite Cost Pressures
UHS tops Q2 earnings and revenue estimates as Acute Care and Behavioral Health growth lifts results, even as higher costs weigh on operations.
Zacks
Tenet Healthcare Tops Q2 Earnings Estimates, Raises 2026 Outlook
THC raised its 2026 outlook after Q2 earnings and revenues beat expectations, driven by strong same-facility growth and disciplined expense management.
Zacks
Can Humana Beat Q2 Earnings Estimates on Growing Premiums?
HUM enters Q2 earnings with strong premium and membership growth expectations, but rising medical costs and expenses could test its bottom line.
Zacks
Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises
EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.
Zacks
TMO Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
Thermo Fisher beats Q2 earnings and revenue estimates as organic growth and stronger customer activity lift results, sending shares higher in pre-market trading.
Zacks
Monday 7/20 Insider Buying Report: ELV, FCEL
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At Elevance Health, a filing with the SEC revealed that on Friday, CEO Gail Boudrea...
Nasdaq News: Markets
<
1
2
>

Advertisement|Remove ads.